Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Debt (2019 - 2024)

Seres Therapeutics (MCRB) has disclosed Non-Current Debt for 7 consecutive years, with $102.5 million as the latest value for Q2 2024.

  • Quarterly Non-Current Debt rose 1.74% to $102.5 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $102.5 million through Jun 2024, up 1.74% year-over-year, with the annual reading at $101.5 million for FY2023, 100.72% up from the prior year.
  • Non-Current Debt hit $102.5 million in Q2 2024 for Seres Therapeutics, roughly flat from $102.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $102.5 million in Q2 2024 to a low of $16.1 million in Q3 2021.
  • Historically, Non-Current Debt has averaged $52.4 million across 5 years, with a median of $50.5 million in 2022.
  • Biggest five-year swings in Non-Current Debt: tumbled 35.47% in 2021 and later surged 215.55% in 2022.
  • Year by year, Non-Current Debt stood at $24.6 million in 2020, then increased by 0.02% to $24.6 million in 2021, then soared by 105.3% to $50.6 million in 2022, then soared by 100.72% to $101.5 million in 2023, then grew by 0.94% to $102.5 million in 2024.
  • Business Quant data shows Non-Current Debt for MCRB at $102.5 million in Q2 2024, $102.0 million in Q1 2024, and $101.5 million in Q4 2023.